Tag: Japan pharma
Edesa hands Kyorin Japan rights to its phase 3 respiratory antibody
The deal is worth up to $140M plus royalties for paridiprubart, an experimental treatment aimed at acute respiratory distress syndrome.
The deal is worth up to $140M plus royalties for paridiprubart, an experimental treatment aimed at acute respiratory distress syndrome.